Week in review: Retinoblastoma survival rates, generic of Restasis approved, prematurity leads to long-term vision problems
- Posted on: Feb 4 2022
- Leave a response
This week, global retinoblastoma survival disparities remain despite progress. the first generic for Restasis is approved in the US, and ophthalmic problems due to prematurity persist into adulthood.
Source: AAO
Posted in: Uncategorized